Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Mipletamig Regimen Yields Clinical Benefit in Frontline AML Trial

Summary by cancernetwork.com
Investigators are on track to complete the phase 1b dose-escalation portion of the RAINIER trial in 2026.

4 Articles

Jonesboro SunJonesboro Sun
+2 Reposted by 2 other sources
Lean Right

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

Program Enters Final Stage of Dose Optimization

Read Full Article
cancernetwork.comcancernetwork.com

Mipletamig Regimen Yields Clinical Benefit in Frontline AML Trial

Investigators are on track to complete the phase 1b dose-escalation portion of the RAINIER trial in 2026.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Jonesboro Sun broke the news on Wednesday, May 6, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Alexandria, VA icon

Alexandria, VA

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal